How to buy XOMA Corporation stock | $24.71

XOMA Corporation is a biotechnology business based in the US. XOMA Corporation shares (XOMA) are listed on the NASDAQ and all prices are listed in US Dollars. XOMA Corporation employs 11 staff and has a trailing 12-month revenue of around 0.00.

XOMA Corporation stock price (NASDAQ: XOMA)

Use our graph to track the performance of XOMA stocks over time.

XOMA Corporation shares at a glance

• Key figures

Information last updated 2021-10-17.

Latest market close	$24.71
52-week range	$19.26 - $46.32
50-day moving average	$25.54
200-day moving average	$30.98
Wall St. target price	$62.50
PE ratio	52.7403
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.49

Buy XOMA Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy XOMA Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

XOMA Corporation price performance over time

Historical closes compared with the close of $24.71 from 2021-10-22

1 week (2021-10-15)	-4.19%
1 month (2021-09-24)	0.90%
3 months (2021-07-23)	-26.02%
6 months (2021-04-23)	-33.74%

1 year (2020-10-23)	9.53%
2 years (2019-10-23)	28.36%
3 years (2018-10-23)	76.88%
5 years (2016-10-21)	352.56%

Is XOMA Corporation under- or over-valued?

Valuing XOMA Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of XOMA Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

XOMA Corporation's P/E ratio

XOMA Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 53x. In other words, XOMA Corporation shares trade at around 53x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

XOMA Corporation's EBITDA

XOMA Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.7 million.

The EBITDA is a measure of a XOMA Corporation's overall financial performance and is widely used to measure a its profitability.

XOMA Corporation financials

Revenue TTM	$29.4 million
Operating margin TTM	39.75%
Gross profit TTM	$29.2 million
Return on assets TTM	6.53%
Return on equity TTM	15.46%
Profit margin	40.73%
Book value	$10.30
Market capitalisation	$291.7 million

TTM: trailing 12 months

Shorting XOMA Corporation shares

There are currently 368,064 XOMA Corporation shares held short by investors – that's known as XOMA Corporation's "short interest". This figure is 3.6% down from 381,927 last month.

There are a few different ways that this level of interest in shorting XOMA Corporation shares can be evaluated.

XOMA Corporation's "short interest ratio" (SIR)

XOMA Corporation's "short interest ratio" (SIR) is the quantity of XOMA Corporation shares currently shorted divided by the average quantity of XOMA Corporation shares traded daily (recently around 30851.969823973). XOMA Corporation's SIR currently stands at 11.93. In other words for every 100,000 XOMA Corporation shares traded daily on the market, roughly 11930 shares are currently held short.

However XOMA Corporation's short interest can also be evaluated against the total number of XOMA Corporation shares, or, against the total number of tradable XOMA Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case XOMA Corporation's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 XOMA Corporation shares in existence, roughly 30 shares are currently held short) or 0.0513% of the tradable shares (for every 100,000 tradable XOMA Corporation shares, roughly 51 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against XOMA Corporation.

Find out more about how you can short XOMA Corporation stock.

XOMA Corporation share dividends

We're not expecting XOMA Corporation to pay a dividend over the next 12 months.

Have XOMA Corporation's shares ever split?

XOMA Corporation's shares were split on a 1:20 basis on 17 October 2016. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your XOMA Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for XOMA Corporation shares which in turn could have impacted XOMA Corporation's share price.

XOMA Corporation share price volatility

Over the last 12 months, XOMA Corporation's shares have ranged in value from as little as $19.255 up to $46.32. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while XOMA Corporation's is 0.9312. This would suggest that XOMA Corporation's shares are less volatile than average (for this exchange).

XOMA Corporation overview

XOMA Corporation, a biotechnology royalty aggregator, engages in helping biotech companies for improving human health. The company acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. It acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance internal drug candidate or for general corporate purposes. The company has a portfolio with approximately 70 assets. It has a pipeline of monoclonal antibodies and technologies available to license to pharmaceutical and biotechnology companies to further clinical development include PTH1R program, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; and X213, an allosteric inhibitor of prolactin action. The company also licenses antibody discovery, optimization, and development technologies. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

Frequently asked questions

What percentage of XOMA Corporation is owned by insiders or institutions?
Currently 5.442% of XOMA Corporation shares are held by insiders and 59.817% by institutions. How many people work for XOMA Corporation?
Latest data suggests 11 work at XOMA Corporation. When does the fiscal year end for XOMA Corporation?
XOMA Corporation's fiscal year ends in December. Where is XOMA Corporation based?
XOMA Corporation's address is: 2200 Powell Street, Emeryville, CA, United States, 94608 What is XOMA Corporation's ISIN number?
XOMA Corporation's international securities identification number is: US98419J2069 What is XOMA Corporation's CUSIP number?
XOMA Corporation's Committee on Uniform Securities Identification Procedures number is: 98419J107